CA2595699A1 - Compositions, kits and methods for identification, assessment, prevention and therapy of cancer - Google Patents

Compositions, kits and methods for identification, assessment, prevention and therapy of cancer Download PDF

Info

Publication number
CA2595699A1
CA2595699A1 CA002595699A CA2595699A CA2595699A1 CA 2595699 A1 CA2595699 A1 CA 2595699A1 CA 002595699 A CA002595699 A CA 002595699A CA 2595699 A CA2595699 A CA 2595699A CA 2595699 A1 CA2595699 A1 CA 2595699A1
Authority
CA
Canada
Prior art keywords
marker
cancer
subject
sample
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002595699A
Other languages
English (en)
French (fr)
Inventor
Ronald Depinho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Publication of CA2595699A1 publication Critical patent/CA2595699A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002595699A 2005-02-17 2006-02-17 Compositions, kits and methods for identification, assessment, prevention and therapy of cancer Abandoned CA2595699A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US65422705P 2005-02-17 2005-02-17
US60/654,227 2005-02-17
US69006405P 2005-06-13 2005-06-13
US60/690,064 2005-06-13
PCT/US2006/005584 WO2006089087A2 (en) 2005-02-17 2006-02-17 Compositions, kits and methods for identification, assessment, prevention and therapy of cancer

Publications (1)

Publication Number Publication Date
CA2595699A1 true CA2595699A1 (en) 2006-08-24

Family

ID=36917075

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002595699A Abandoned CA2595699A1 (en) 2005-02-17 2006-02-17 Compositions, kits and methods for identification, assessment, prevention and therapy of cancer

Country Status (5)

Country Link
US (1) US8168602B2 (cg-RX-API-DMAC7.html)
EP (1) EP1855727A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008536480A (cg-RX-API-DMAC7.html)
CA (1) CA2595699A1 (cg-RX-API-DMAC7.html)
WO (1) WO2006089087A2 (cg-RX-API-DMAC7.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007095186A2 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8372582B2 (en) * 2006-08-01 2013-02-12 Joslin Diabetes Center, Inc. Methods of modulating metabolic memory
CA2662236A1 (en) * 2006-09-12 2008-03-20 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
US20100298158A1 (en) * 2007-05-21 2010-11-25 Dana-Farber Cancer Institute, Inc. Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Cancer
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
JP2011001267A (ja) * 2007-10-17 2011-01-06 Univ Of Tokyo 大腸癌治療薬
JP5586164B2 (ja) * 2009-04-06 2014-09-10 聡明 渡邉 潰瘍性大腸炎患者の癌化リスクを決定する方法
US20120100999A1 (en) * 2009-04-20 2012-04-26 University Health Network Prognostic gene expression signature for squamous cell carcinoma of the lung
CN102906275A (zh) 2010-02-10 2013-01-30 加利福尼亚大学董事会 肺癌检测的唾液生物标记
IL243203A (en) 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
US8709718B1 (en) 2011-02-12 2014-04-29 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Method of treating lung cancer
PL2768985T3 (pl) * 2011-10-21 2019-10-31 Chronix Biomedical Biomarkery będące krążącymi kwasami nukleinowymi związane z rakiem jelita grubego
CN107326085B (zh) 2012-02-03 2022-05-03 加州理工学院 多路生化测定中信号的编码和解码
EP3129908B1 (en) * 2014-03-25 2021-07-21 Five3 Genomics, LLC Systems and methods for rna analysis in functional confirmation of cancer mutations
GB201521894D0 (en) 2015-12-11 2016-01-27 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against various cancers
IL298653A (en) 2015-12-11 2023-01-01 Immatics Biotechnologies Gmbh New peptides and a combination of peptides for use in immunotherapy against several types of cancer
US20210208162A1 (en) * 2016-01-19 2021-07-08 Global Down Syndrome Foundation Down syndrome biomarkers and uses thereof
EP3203413A1 (en) * 2016-02-08 2017-08-09 Ecole Polytechnique Federale De Lausanne (Epfl) Method for quantitative measurement of a biomarker by in situ immunofluorescence and uses thereof
WO2019067092A1 (en) 2017-08-07 2019-04-04 The Johns Hopkins University METHODS AND SUBSTANCES FOR THE EVALUATION AND TREATMENT OF CANCER
CN109125729A (zh) * 2018-09-06 2019-01-04 苏州吉玛基因股份有限公司 与非小细胞肺癌诊疗相关的基因BRD9及其siRNAs和应用
JP7262736B2 (ja) * 2018-10-31 2023-04-24 公立大学法人北九州市立大学 癌の診断を補助する方法、および癌を診断するシステム
EP4005634A4 (en) * 2019-07-24 2023-11-08 Tohoku University Chimeric molecule, pharmaceutical composition, method for cleaving target nucleic acid, and kit for target nucleic acid cleavage or diagnosis
CN110317876A (zh) * 2019-08-02 2019-10-11 苏州宏元生物科技有限公司 一组染色体不稳定变异在制备诊断多发性骨髓瘤、评估预后的试剂或试剂盒中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6602713B1 (en) * 2001-02-09 2003-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of protein phosphatase 2 catalytic subunit beta expression
US5783683A (en) * 1995-01-10 1998-07-21 Genta Inc. Antisense oligonucleotides which reduce expression of the FGFRI gene
TW200533376A (en) * 2004-03-24 2005-10-16 Oncotherapy Science Inc Compositions and methods for treating lung cancer
US8999633B2 (en) * 2004-05-28 2015-04-07 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans

Also Published As

Publication number Publication date
EP1855727A2 (en) 2007-11-21
US20090297525A1 (en) 2009-12-03
JP2008536480A (ja) 2008-09-11
WO2006089087A9 (en) 2010-02-04
WO2006089087A2 (en) 2006-08-24
US8168602B2 (en) 2012-05-01

Similar Documents

Publication Publication Date Title
US9309564B2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8168602B2 (en) Compositions, kits and methods for identification, assessment, prevention and therapy of cancer
US7705120B2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
Manne et al. Development and progression of colorectal neoplasia
WO2010045470A2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders
US20080242742A1 (en) Animal models of pancreatic adenocarcinoma and uses therefor
EP2531858B1 (en) Identification, assessment, and therapy of cancers with innate or acquired resistance to alk inhibitors
US20100298158A1 (en) Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Cancer
US8999633B2 (en) Compositions, kits, and methods for identification, assessment, prevention and treatment of pancreatic adenocarcinoma in humans
WO2004106495A2 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP2012504426A (ja) Ｇｏｌｐｈ３を使用する癌の診断、予後およびモニタリングのための組成物、キットおよび方法
Falchetti et al. Telomerase repeat amplification protocol (TRAP): a new molecular marker for parathyroid carcinoma
Hosoi et al. Suppression of anchorage-independent growth by expression of the ataxia-telangiectasia group D complementing gene, ATDC
Fong et al. Molecular basis of lung carcinogenesis
WO2022207760A1 (en) Genomic predictor of outcome in cancer
Matsuda The Association of Single Nucleotide Polymorphisms with Cancer Risk
Shames et al. The molecular genetics of lung cancer
Gutierrez et al. Molecular Genetics and Cytogenetics in Cancer
Grundy The molecular genetics of wilms tumour and the wilms tumour predisposition syndromes

Legal Events

Date Code Title Description
FZDE Discontinued